Patient benefit as a goal of humanization
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- David Gil-Sierra, Manuel
- del Pilar Briceno-Casado, Maria
Abstract
Patient empowerment is one of the main pillars of humanisation. Therefore, consideration of patients' preferences and expectations should be taken into account during the practice of any healthcare professional. Improving overall survival and quality of life are the main wishes of patients. Indeed, the recent emergence of Patient Reported Outcomes has become an important focus for healthcare providers. The hospital pharmacist specialised in drug evaluation is a professional who evaluates the efficacy, safety, appropriateness and efficiency of treatments prescribed by physicians, and decision-making must be based on both technical factors and the four principles of bioethics. The correct application of evidence-based clinical practice allows to provide patients with increases in survival and/or quality of life, adapting the convenience and costs to the current situation. With this in mind, it could be said that the evaluation of medicines involves a strong commitment to humanisation. On the other hand, organisations that promote the rigorous evaluation and selection of medicines stand as allies of patients, as they have a direct impact on them and an indirect impact on society. Regulatory agencies in charge of approving and financing medicines in healthcare systems play a key role in the process of humanising clinical decision-making and empowering patients. If these agencies approve the use of new medicines based on data that do not measure quality of life or survival of patients when there are already other therapeutic alternatives for these pathologies, they are indirectly failing to meet patients' expectations and are infringing bioethical principles. This can have a considerable influence on the benefit-risk ratio of drugs, andvencia de los pacientes cuando ya existen otras alternativas terapeuticas para estas patologlas, indirectamente no estaran dando respuesta a las expectativas de los pacientes y conculcaran los principios bioeticos. Esto puede tener una considerable influencia en la relacion beneficio-riesgo de los farmacos, pudiendo tratar a pacientes con esquemas que no aportan beneficio, o incluso podrlan perjudicarles. Por tanto, inverted question mark hacia donde debiera ir orientado el proceso de humanizacion? Parece razonable que el benefi-cio del paciente sea el objetivo fundamental del proceso de humanizacion de la asistencia sanitaria, evidentemente.
Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 1130-6343, 0214-753X
- Tipo:
- Article
- Páginas:
- 367-371
- DOI:
- 10.7399/fh.13171
- PubMed:
- 36520577
- Factor de Impacto:
- 0,264 SCImago ℠
- Cuartil:
- Q3 SCImago ℠
FARMACIA HOSPITALARIA EDITORIAL GARSI
Documentos
- No hay documentos
Filiaciones
Keywords
- Patient; Humanisation; Patient-centered care; Empowerment; Bioethics; Evidence-based medicine; Drug evaluation
Proyectos y Estudios Clínicos
APLICACIÓN DE LA NANOTECNOLOGÍA AL TRATAMIENTO DE RETINOSIS PIGMENTARIA CON ANTICUERPOS ANTI_TNF ALFA. EFECTO SINÉRGICO CON ANTIOXIDANTES
Investigador Principal: REGINA RODRIGO NICOLÁS
PI15/00052 . INSTITUTO DE SALUD CARLOS III . 2016
Predict I-O: Predicción de la Respuesta a la Terapia en Inmuno-Oncología. Desarrollo de un modelo para la sostenibilidad del sistema de salud.
Investigador Principal: SARAI PALANCA SUELA
GV/2021/144 . CONSELLERIA DE INNOVACIÓN, UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL . 2021
PARACETAMOL VERSUS IBUPROFENO EN RECIÉN NACIDOS PREMATUROS CON DIAGNÓSTICO DE DUCTUS ARTERIOSO PERSISTENTE HEMODINÁMICAMENTE SIGNIFICATIVO: ENSAYO CLÍNICO ALEATORIZADO.
Investigador Principal: MARTA AGUAR CARRASCOSA
IBUPAR-TRIAL . 2017
REGISTRO PROSPECTIVO DE EFECTOS ADVERSOS ASOCIADOS CON LA INFUSIÓN DE DEXRAZOXANO EN POBLACIÓN PEDIÁTRICA CON LEUCEMIA MIELOBLÁSTICA AGUDA.
Investigador Principal: JOSÉ MARÍA FERNÁNDEZ NAVARRO
JFN-DEX-2020-01 . 2021
SEHOP-PENCIL study: Personalised mEdicine for Cancer in children in Spain.
Investigador Principal: ADELA CAÑETE NIETO
PMP21/00073 . INSTITUTO DE SALUD CARLOS III . 2022
Cita
David Gil M,del Pilar Briceno M,LOPEZ E. Patient benefit as a goal of humanization. Farm. Hosp. 2022. 46. (6):p. 367-371.